Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women [0.03%]
年轻女性人群中饮食和生活方式指数与结直肠癌发病风险的前瞻性研究
Y Yue,J Hur,Y Cao et al.
Y Yue et al.
Background: Although colorectal cancer (CRC) incidence in the USA is declining overall, its incidence is increasing among those younger than 50 years of age. The reasons underlying the increasing trend are largely unknown...
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma [0.03%]
基于抗PD-1的免疫治疗在黑色素瘤中延迟出现的免疫相关不良事件
C N Owen,X Bai,T Quah et al.
C N Owen et al.
Background: Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4...
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy [0.03%]
基于PD-L1表达胃食管腺癌具有不同的基因组特征确定RAS-MAPK信号通路和TP53的突变可能是免疫治疗疗效预测标志物
J Y Wang,J Xiu,Y Baca et al.
J Y Wang et al.
Background: The impact of molecular alterations on programmed death-ligand 1 (PD-L1) combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features ...
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial [0.03%]
醋酸阿比特龙治疗转移性去势抵抗性前列腺癌一线患者后的血浆肿瘤基因转换：一项国际多中心临床试验的生物标志物分析结果
A Jayaram,A Wingate,D Wetterskog et al.
A Jayaram et al.
Background: Plasma tumor DNA fraction is prognostic in metastatic cancers. This could improve risk stratification before commencing a new treatment. We hypothesized that a second sample collected after one cycle of treatm...
Checkpoint inhibition: protecting against or predisposing for second primary tumors? [0.03%]
检查点抑制：防止或促发继发性原发肿瘤？
K P M Suijkerbuijk,A M May,M J M van Eijs
K P M Suijkerbuijk
A Di Vincenzo,A Andrisani,R Vettor et al.
A Di Vincenzo et al.
A B Carpenter,A M Carpenter,R Aiken et al.
A B Carpenter et al.
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect ...
Immunotherapy use outside clinical trial populations: never say never? [0.03%]
免疫治疗临床试验以外的使用：永不言永不再试？
K Rzeniewicz,J Larkin,A M Menzies et al.
K Rzeniewicz et al.
Background: Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, are now widel...
F Dimitriou,G V Long,A M Menzies
F Dimitriou
Background: Patients with resected stage III and IV melanoma have a high risk of recurrence. As the outcomes for patients with metastatic disease have improved dramatically over the past decade due to systemic therapy, mo...
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium [0.03%]
癌症患者中临床因素和最近的抗癌治疗与新冠肺炎严重程度的关系：来自“新冠肺炎与癌症联盟”的一份报告
P Grivas,A R Khaki,T M Wise-Draper et al.
P Grivas et al.
Background: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVI...